Clinical Trials Directory

Trials / Completed

CompletedNCT04253197

Ultrasound Staging in the Placenta Accreta

Efficacy of Ultrasound Staging System in Prediction of Morbidly Adherent Placenta

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
75 (actual)
Sponsor
Beni-Suef University · Academic / Other
Sex
Female
Age
18 Years – 45 Years
Healthy volunteers
Not accepted

Summary

The investigators evaluated the efficacy of a staging system introduced by the American Institute of ultrasound in medicine 2015 including sonographic parameters associated with morbidly adherent placenta for antenatal prediction of placental invasion.

Detailed description

Morbidly adherent placenta (MAP) defines a spectrum of conditions, including placenta accreta, increta, and percreta, which are associated with significant maternal and fetal morbidity and mortality. Ultrasound evaluation, with grayscale, is the recommended first-line modality for diagnosing MAP. Grayscale ultrasound features suggestive of placenta accreta include the loss of myometrial interface or retroplacental clear space, reduced myometrial thickness and the presence of intraplacental lacunae. Using a staging system by antenatal ultrasound can predict placental invasion antenatally.

Conditions

Interventions

TypeNameDescription
DEVICEUltrasoundPregnant women in 3rd trimester with anterior placenta previa and lower cesarean section scar. Ultrasound was done and according to parameters of the morbidly adherent placenta, a staging system was conducted.

Timeline

Start date
2017-03-14
Primary completion
2019-07-20
Completion
2019-12-25
First posted
2020-02-05
Last updated
2020-02-05

Locations

1 site across 1 country: Egypt

Source: ClinicalTrials.gov record NCT04253197. Inclusion in this directory is not an endorsement.